Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates

Transplantation

Volumn 88, Issue 12, 2009, Pages 1349-1359

  Kim, Jung Sik ^a,b   Lee, Jae Il ^b   Shin, Jin Young ^a,b   Kim, Su Young ^a,b   Shin, Jun Seop ^a,b   Lim, Jong Hyung ^a,b   Cho, Hyoung Soo ^a,b   Yoon, Il Hee ^a,b   Kim, Ki Hyun ^c   Kim, Sang Joon ^b   Park, Chung Gyu ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bortezomib; Memory T cell; Proteasomal inhibitor; Rapamycin; Regulatory T cell

Indexed keywords

BORTEZOMIB; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; BORONIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHESUS MONKEY; ANIMAL; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; GRAFT REJECTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACACA; MALE; MINIPIG; PANCREAS TRANSPLANTATION; PATHOLOGY; PHYSIOLOGY; SWINE; T LYMPHOCYTE;

ANIMALS; BORONIC ACIDS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; GRAFT REJECTION; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MALE; PANCREAS TRANSPLANTATION; PROTEASE INHIBITORS; PYRAZINES; SIROLIMUS; SWINE; SWINE, MINIATURE; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 74049101534     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181bd7b3a     Document Type: Article

References (45)

1. Barten MJ, Streit F, Boeger M, et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: Analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation 2004; 77: 1154.
2. Vu MD, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64: 1853.
3. Schuurman HJ, Menninger K, Audet M, et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotrans-plantation, given alone or in combination with cyclosporine or RAD. Transplantation 2002; 74: 951.
4. Sho M,Sandner SE, Najafian N, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosup-pressive drugs. Ann Surg 2002; 236: 667.
5. Greenlaw RE, Gardner NJ, Farrar CA, et al. An antibody combination that targets activated T cells extends graft survival in sensitized recipients. Am J Transplant 2008; 8: 2272.
6. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7: 1722.
7. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 2008; 22: 125.
8. Vasquez EM. Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000; 57: 437.
9. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006; 55: 2429.
10. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005; 201: 259.
11. SlavikJM, Lim DG, Burakoff SJ, et al. Uncoupling p70(s6) kinase activation and proliferation: Rapamycin-resistant proliferation of human CD8( + ) T lymphocytes. J Immunol 2001; 166:3201.
12. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682.
13. SlavikJM, Lim DG, Burakoff SJ, et al. Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. J Biol Chem 2004; 279: 910.
14. Uddin S, Ahmed M, Bavi P, et al. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008; 68: 3379.
15. Egan LJ, Toruner M. NF-kappaB signaling: Pros and cons of altering NF-kappaB as a therapeutic approach. Ann NY Acad Sci 2006; 1072: 114.
16. Li Q, VermaIM. NF-kappaB regulation in the immune system. Nat Rev Immunol2002; 2: 725.
17. Macian F, Garcia-Cozar F, Im SH, et al. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002; 109: 719.
18. Sundstedt A, Sigvardsson M, Leanderson T, et al. In vivo anergized CD4+ T cells express perturbed AP1 and NF-kappa B transcription factors. Proc Natl Acad Sci USA 1996; 93: 979.
19. Zhou P, Hwang KW, Palucki DA, et al. Impaired NF-kappaB activation in T cells permits tolerance to primary heart allografts and to secondary donor skin grafts. Am J Transplant 2003; 3: 139.
20. Yoshimura S, Bondeson J, Brennan FM, et al. Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol 2001; 31: 1883.
21. Iruretagoyena MI, Sepulveda SE, Lezana JP, et al. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther2006; 318: 59.
22. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120.
23. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535.
24. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: A new anti-inflammatory strategy. J Mol Med 2003; 81: 235.
25. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575.
26. Subklewe M, Sebelin-Wulf K, Beier C, et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 2007; 68: 147.
27. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748.
28. Wu Y, Han B, Luo H, et al. Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection. Transplantation 2004; 78: 360.
29. Zweegman S, Janssen JJ, Lokhorst HM. Immune-modulatory effects of bortezomib in GVHD. Leuk Lymphoma 2007; 48: 853.
30. Kim HI, Lee SY, Jin SM, et al. Parameters for successful pig islet isolation as determined using 68 specific-pathogen-free miniature pigs. Xenotransplantation 2009; 16: 11.
31. Casu A, Bottino R, Balamurugan AN, et al. Metabolic aspects of pig-to-monkey (Macaca fascicularis) islet transplantation: Implications for translation into clinical practice. Diabetologia 2008; 51: 120.
32. Acierno PM, Schmitz JE, Gorgone DA, et al. Preservation of functional virus-specificmemoryCD8+ T lymphocytes in vaccinated, simianhuman immunodeficiency virus-infected rhesus monkeys. J Immunol 2006; 176: 5338.
33. Richardson PG, Mitsiades C, Hideshima T, et al. Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57:33.
34. Bingaman AW, Farber DL. Memory T cells in transplantation: Generation, function, and potential role in rejection. Am J Transplant 2004; 4:846.
35. Valujskikh A. The challenge of inhibiting alloreactive T-cell memory. Am J Transplant 2006; 6: 647.
36. Calvo V, Crews CM, Vik TA, et al. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proc Natl Acad Sci USA 1992; 89: 7571.
37. Valmori D, Tosello V, Souleimanian NE, et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4 + T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006; 177: 944.
38. Blaha P, Bigenzahn S, Koporc Z, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101:2886.
39. Li M, Zhang X, Zheng X, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol 2007; 178: 5480.
40. Isomura I, Morita A. Regulation of NF-kappaB signaling by decoy oligodeoxynucleotides. Microbiol Immunol 2006; 50: 559.
41. Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008; 29: 628.
42. Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32.
43. Fujimoto M, Serada S, Naka T. [Role of IL-6 in the development and pathogenesis of CIA and EAE]. Nihon Rinsho Meneki Gakkai Kaishi 2008; 31: 78 (in Japanese).
44. Yokota S. [Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis]. Nihon Rinsho Meneki Gakkai Kaishi 2008; 31: 99 (in Japanese).
45. XiaoW,Hodge DR, WangL,et al. NF-kappaB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFkappaB regulatory site in autocrine human multiple myeloma cells. Cancer Biol Ther 2004; 3: 1007.